Background—We investigated the effects of asialoerythropoietin (asialoEPO), a
nonerythrogenic erythropoietin derivative, on 3 murine models of heart failure with different …

Objectives: We examined the effect of asialoerythropoietin (asialoEPO), a nonerythrogenic
derivative of erythropoietin (EPO), on renal dysfunction-associated heart failure …

Asialoerythropoietin (asialo-EPO) is a desialylated form of human glycoprotein hormone
erythropoietin (EPO), which has been reported to be neuro-, cardio-, and renoprotective in …

The hormone erythropoietin (EPO) has been demonstrated to have cardioprotective
properties. The present study investigates the role of EPO to prevent heart failure following …

Purpose Although erythropoietin (EPO) is known to express angiogenic and cardioprotective
effects, it also induces hypertension, polycythemia, and platelet activation, which may cause …

Besides stimulating erythropoiesis, erythropoietin (EPO) exerts powerful proangiogenic and
antiapoptotic effects. These erythropoiesis-independent effects are potentially useful as a …

Erythropoietin (EPO) is a 30.4-kDa glycoprotein essential for red blood cell production. In
adults, EPO is produced primarily in the kidney via an oxygen-sensing mechanism and …

Erythropoietin (EPO) is not solely a hormone charged with regulating the proliferation and
differentiation of erythroid cells. Indeed, EPO is synthesized locally by many cells, especially …

Objectives Late treatment with erythropoietin (EPO), as well as the administration before the
onset of or during the acute stage of myocardial infarction (MI), has recently been shown to …

Background: Erythropoietin (EPO) may improve cardiac function and induce
neovascularisation in experimental models of chronic heart failure (CHF). However, the …